Validated Assays, Specimen Handling Procedures and Reagent Sources for Intact MET, Dual Phospho-Y1234/Y1235 and Phospho-Y1356 Immunoassays

• Intact MET Solid Tumor Assessment

  The Intact MET Immunoassay has been developed to measure the effect of anticancer agents on the levels of intact MET in tumor biopsy samples, irrespective of the MET phosphorylation levels. The amount of intact MET measured will serve as a denominator reading to determine the fraction of MET phosphorylated at critical sites.

  1. Specimen Collection
  2. Sample Preparation
  3. Immunoassay SOP
  4. Data Analysis, Quality Control, and Reporting SOP

   

• Dual Phospho-Y1234/1235 MET Solid Tumor Assessment

  The Dual Phospho-Y1234/Y1235 MET Immunoassay has been developed to measure the effects of anticancer agents on pMET levels in MET-overexpressed/amplified disease conditions in tumor biopsy samples. The amount of intact MET measured in Intact MET Immunoassay will serve as a denominator reading to determine the fraction of dual phospho-Y1234/Y1235 MET in the samples.

  1. Specimen Collection
  2. Sample Preparation
  3. Immunoassay SOP
  4. Data Analysis, Quality Control, and Reporting SOP

   

• Phospho-Y1356 MET Solid Tumor Assessment

  The Phospho-Y1356 MET Immunoassay has been developed to measure the effect of anticancer agents on pMET levels in MET-overexpressed/amplified disease conditions in tumor biopsy samples. The amount of intact MET measured in Intact MET Immunoassay will serve as a denominator reading to determine the fraction of phospho-Y1356 MET in the samples.

  1. Specimen Collection
  2. Sample Preparation
  3. Immunoassay SOP
  4. Data Analysis, Quality Control, and Reporting SOP

   

• Assay Training and Key Reagent Support
• NCI Publications